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See Articles, pages 589–593 and pages 617–625Two articles in this month’s issue of the Journal reveal new
insights into intracellular pathways in hepatocytes that contrib-
ute to tumorigenesis in an animal model, and provide reassur-
ance about the safety of percutaneous ﬁne needle biopsy in
patients with suspected HCC being evaluated for liver
transplantation.
The ﬁrst article, by Ni et al., investigates the consequences of
blocking autophagy, a vital intracellular degradative pathway,
in hepatocytes of experimental mice, and uncovers Nrf2 as an
important mediator that contributes to the resulting ﬁbrosis
and tumorigenesis. As reviewed in one of my earlier Focus pieces,
autophagy is a well-regulated pathway that helps preserve
energy homeostasis by degrading intracellular substrates when
the cell is stressed or starved [1,2]. A growing number of media-
tor proteins in the autophagy cascade have been uncovered, and
two in particular, Atg5 and Atg7, have been knocked out in sev-
eral studies by using a cre-lox strategy, in which inserted LoxP
sites ﬂank a portion of the coding region – when these ‘ﬂoxed’
mice are crossed with a mouse expressing the albumin promoter
driving Cre recombinase, the gene is speciﬁcally deleted in hepa-
tocytes. Using this approach, Ni and colleagues have character-
ized the phenotype of a hepatocyte-speciﬁc Atg5 knockout
mice. As reported previously with a knockout of Atg7 [3], mice
with loss of Atg5 have gross hepatic morphologic abnormalities,
including cell death, inﬂammation, ﬁbrosis and then hepatic
tumors.
A model of this type provides important opportunities to
determine novel pathways of disease pathogenesis in rodents
that can be used to illuminate our understanding of the human
disease, and the authors have exploited this opportunity to
uncover a role for the protein Nrf2 (nuclear factor erythroid
2–related factor 2) in mediating the phenotype. Nrf2 is a master
transcription factor that drives induction of a range of antioxi-
dant and detoxiﬁcation genes [4,5]. Its activity is normally
restrained by cytoplasmic sequestration through binding to the
intracellular protein Keap1 (kelch-like ECH-associated protein
1), and thus therapeutic strategies that dissociate Keap1 fromJournal of Hepatology 20
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Open access under CC BY-NC-ND license.Nrf2 will enhance its nuclear localization and lead to increased
expression of antioxidant defense genes [5]. Interestingly, earlier
studies demonstrated that when autophagy is inhibited, a speciﬁc
protein called p62 accumulates. This protein targets intracellular
substrates for autophagy, and earlier studies demonstrated that
when p62 accumulates in this setting it binds to Keap1, and thus
liberates Nrf2 for nuclear translocation and activation of target
genes [6]. Therefore, these earlier studies indicate that the exces-
sive activation of Nrf2 arising as a result of autophagy inhibition
might contribute to the phenotype of livers that lack Atg5 or
Atg7.
Ni and colleagues have addressed this possibility elegantly
and deﬁnitively by simply crossing the mice whose livers lack
autophagy with animals that additionally lack Nrf2, creating a
‘double knockout’ mouse. Remarkably, the abnormalities evident
in the Atg5 knockout livers were abrogated when Nrf2 was
absent, clearly indicating that the major defects in these livers
lacking autophagy are attributable to Nrf2; in other words, loss
of Nrf2 rescues the Atg5 knockout phenotype. The authors also
demonstrate that Atg5 is intact in hepatic stellate cells, suggest-
ing that the ﬁbrosis that occurs in Atg5 hepatocyte knockout mice
probably results from stellate cell activation following release of
mediators from damaged hepatocytes, not from altered autoph-
agy in stellate cells. Indeed, autophagy is required for stellate
cells to activate [7]. Moreover, since tumor development is also
abrogated when Nrf2 is lost, the ﬁndings further suggest that
without the severe damage to hepatocytes, combined with elim-
ination of the ﬁbrotic microenvironment, the risk of neoplasia is
mitigated.
The surprising but clear implication of these ﬁndings is that
Nrf2, whose role is to enhance antioxidant and detoxiﬁcation
pathways, also has a dark side when its activity is unrestrained.
The authors propose several credible explanations for this para-
doxical behavior of Nrf2, which should be tested experimentally.
The broader implication is that there is an optimal level of activ-
ity of key autophagic and antioxidant mediators in hepatocytes
required in order to maintain healthy intracellular pathways of
energy and substrate homeostasis. The ﬁndings of Ni et al. yield
valuable insight into these pathways, and also offer a cautionary
tale about the potential deleterious impact of manipulating them
therapeutically without fully understanding the consequences.
Both our understanding of HCC pathogenesis and advances in
its management have been greatly accelerated by uncovering
speciﬁc patterns of liver gene expression that correlate with14 vol. 61 j 457–458
Focus
clinical outcomes [8,9]. Indeed, we are entering an era where
comprehensive assessment of gene expression patterns both in
the tumor and in the surrounding stroma of HCC will help per-
sonalize therapy and reﬁne the prediction of recurrence after sur-
gery or transplantation. For example, a ‘favorable’ gene signature
in the stroma or tumor in a patient whose HCC exceeds Milan cri-
teria could reinstate the possibility of liver transplantation. Of
course, biopsy is required to obtain these gene expression signa-
tures preoperatively. So it is ironic that genetic information
assessed from biopsies is becoming very valuable at a time when
the deﬁnitive diagnosis of HCC no longer requires tissue conﬁr-
mation, making routine biopsies less common in diagnosing this
tumor. Concerns about performing directed biopsy of suspicious
lesions have included the possibility of not accessing the tumor
and of bleeding or other complications. Another concern has been
the risk of tracking tumor cells along the needle path, thereby
worsening the prognosis prior to attempts at curative therapy.
Studies estimate a risk of needle track seeding of 2.3–2.7% when
performing liver biopsy to diagnose HCC [10,11].
The article by Fuks et al. from Hopital Beaujon in Paris in this
issue of the Journal examines the risk of biopsy in a different, but
very sensible way by asking, ‘‘Do patients who have a percutane-
ous needle biopsy for HCC diagnosis prior to listing for liver
transplantation have a poorer outcome than those who did not
have a biopsy?’’. The authors address this question by comparing
the outcomes among 309 patients listed for liver transplantation,
80 of whom underwent pre-operative percutaneous ﬁne needle
aspiration biopsy, and 229 patients of whom did not, with each
group matched for several key variables that could inﬂuence out-
comes, although they were not matched for tumor stage. Among
the 309 patients, 278 were eventually transplanted, and the sur-
vival and rates of tumor recurrence were not affected by whether
the patient had a biopsy in either transplanted or non-trans-
planted patients.
While the study is relatively small and from a single center,
the ﬁndings nonetheless suggest that percutaneous biopsy does
not alter the outcome in patients with suspected HCC who are
being evaluated for liver transplantation. Although the risk of
tumor cell tracking by biopsy is real, its overall impact is likely
to be modest in this setting. Moreover, as the value of genetic
and diagnostic information available from biopsies continues to
increase, investigators should not be dissuaded from incorporat-
ing biopsy into prognostic and management algorithms if it will458 Journal of Hepatology 201greatly improve risk stratiﬁcation or decision-making. As they
do so, larger data sets should be accumulated to conﬁrm the
safety of biopsy in the preoperative management of liver trans-
plantation candidates with suspected HCC, while also tracking
whether the additional information gained from biopsy improves
patient selection and outcomes.Conﬂict of interest
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